Regulus Therapeutics Inc. (RGLS) saw its loss widen to $20.02 million, or $0.38 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $7.23 million, or $0.14 a share.
Revenue during the quarter plunged 99.83 percent to $0.02 million from $10.86 million in the previous year period.
Operating loss for the quarter was $19.74 million, compared with an operating loss of $7.36 million in the previous year period.
"2016 was a year of accomplishments and important key learnings that position us for meaningful advancements in our clinical and pre-clinical programs in 2017 and beyond. Based on these learnings, I am even more convinced that targeting microRNAs offer significant advancements in therapeutic potential for many diseases for which there are currently no or limited treatment options," said Paul Grint, M.D., president and chief executive officer of Regulus.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]